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Trine Bernholdt Rasmussen1,2, Christian Hassager1, Lars Køber1, Daniel Steinbrüchel5, Christian Gluud6, Per Winkel6,
Lau Caspar Thygesen3, Jane Lindschou Hansen6, Jean Paul Schmid7, Viviane Conraads8,
Barbara Christina Brocki9 and Ann-Dorthe Zwisler1,3Abstract
Background: Heart valve diseases are common with an estimated prevalence of 2.5% in the Western world. The
number is rising due to an ageing population. Once symptomatic, heart valve diseases are potentially lethal, and
heavily influence daily living and quality of life. Surgical treatment, either valve replacement or repair, remains the
treatment of choice. However, post surgery, the transition to daily living may become a physical, mental and social
challenge. We hypothesise that a comprehensive cardiac rehabilitation programme can improve physical capacity
and self-assessed mental health and reduce hospitalisation and healthcare costs after heart valve surgery.
Methods: A randomised clinical trial, CopenHeartVR, aims to investigate whether cardiac rehabilitation in addition to
usual care is superior to treatment as usual after heart valve surgery. The trial will randomly allocate 210 patients, 1:1
intervention to control group, using central randomisation, and blinded outcome assessment and statistical analyses.
The intervention consists of 12 weeks of physical exercise, and a psycho-educational intervention comprising five
consultations. Primary outcome is peak oxygen uptake (VO2 peak) measured by cardiopulmonary exercise testing with
ventilatory gas analysis. Secondary outcome is self-assessed mental health measured by the standardised questionnaire
Short Form 36. Also, long-term healthcare utilisation and mortality as well as biochemistry, echocardiography and
cost-benefit will be assessed. A mixed-method design is used to evaluate qualitative and quantitative findings
encompassing a survey-based study before the trial and a qualitative pre- and post-intervention study.
Discussion: The study is approved by the local regional Research Ethics Committee (H-1-2011-157), and the Danish
Data Protection Agency (j.nr. 2007-58-0015).
Trial registration: ClinicalTrials.gov (NCT01558765).
Keywords: Heart valve surgery, Rehabilitation, Physical exercise, Psycho-educationBackground
Heart valve diseases are common with an estimated
prevalence of 2.5% in the Western world population [1].
The number is rising due to an ageing population, thus
leading to a growing public health problem [2]. Once
symptomatic, heart valve diseases affect exercise toler-
ance. In the case of aortic stenosis, the disease may lead* Correspondence: kirstine.laerum.sibilitz@rh.regionh.dk
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reproduction in any medium, provided the orto sudden death. Symptomatic heart valve disease heav-
ily influences the performance of daily living and quality
of life. Surgical treatment, either valve replacement or
repair, remains the treatment of choice [3]. Following
surgery, the transition to daily living may become a
physical, mental and social challenge [4-6].
Clinical guidelines emphasise the importance of
specialised rehabilitation after valvular surgery [7], al-
though randomised clinical trials on rehabilitation
after heart valve surgery are few in number. Current
guidelines on cardiac rehabilitation in valvular heartLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clinical trials on cardiac rehabilitation in patients with
coronary artery disease [8] and congestive heart failure
[9]. However, it is questionable whether the results
from these trials are transferable to a heart valve
surgery population.
Patients undergoing heart valve surgery commonly
present with impairment of physical activity and physical
capacity up to several years before surgery [10]. Com-
bined with a period of bed rest after surgery, this patient
group is therefore not in an optimum state of physical
fitness at hospital discharge and physical rehabilitation is
required [11].
Previous clinical studies concerning the effect of phys-
ical exercise have shown positive impact of exercise
training on quality of life and exercise tolerance [12,13]
in patients after after heart valve surgery, being safe and
not deteriorating the outcome of recent surgery [13]. A
small randomised clinical trial by Landry et al., including
20 patients after aortic valve replacement, found that ex-
ercise capacity measured by work load and peak oxygen
uptake (VO2 peak) increased by up to 5.0 mL/kg/min
(23%) after a physical exercise programme [14]. An ob-
servational study by Habel-Verge et al. of 19 women
after mitral valve replacement, found that mean peak
VO2 increased by 4.0 mL/kg/min [15]. Newell et al.
found similar results in a randomised clinical trial with
24 patients after mitral or aortic valve replacement [10].
Functional evaluation studies after heart valve surgery
such as conducted by Niemela et al. also show improve-
ments in left ventricular ejection fraction and a con-
comitant decrease in New York Heart Association Class
with physical exercise [16].
Furthermore, patients after heart valve surgery can
experience difficulties returning to daily living [4,17-19].
Impaired quality of life, depressive symptoms or overt
depression, anxiety and post-traumatic stress disorder,
can be observed. We therefore hypothesize that consul-
tations focusing on disease management, coping strat-
egies and individually tailored information are needed to
better support mental and psychological recovery.
Seven randomised trials have been identified that
focused on rehabilitation after heart valve surgery
[6,10,14,15,20-22]. However, none of these combine
physical exercise training with psycho-educational
intervention after heart valve surgery. Furthermore,
the trials are narrowly focused, and conducted among
highly selected small trial populations with a lower
mean age than the average heart valve surgery popula-
tion. The general applicability of these trials is limited
and they must be considered as pilot studies.
Thus, a large-scale randomised trial is needed to investi-
gate the effect of cardiac rehabilitation after heart valve sur-
gery. We therefore designed The CopenHeartVR (VR=valvular replacement or repair) trial to investigate the effect
of comprehensive cardiac rehabilitation consisting of both
physical exercise and a psycho-educational component.
This large-scale randomised clinical trial will ascertain
whether comprehensive cardiac rehabilitation is superior
to treatment as usual for a broad group of patients under-
going isolated heart valve surgery. Isolated heart valve
surgery refers to no simultaneous coronary artery bypass
surgery.
Methods
Major parts of the methods section and trial design in
this paper are similar to two other randomised clinical
trials, CopenHeartRFA and CopenHeartIE, and therefore
sections from this paper will be identical in these trial
protocols [23,24].
Due to the differences in the three patient groups in
the three randomised clinical trials, the intervention and
outcome measures differ slightly, most importantly with
regard to the psycho-educational intervention, which is
longer for patients treated for infective endocarditis, be-
cause of the complexity of the disease and the longer
hospitalisation. Biochemical markers are similarly chosen
differently to address the different co-morbidities of the
three different patient groups.
Ethical considerations
The study is approved by the local regional Research
Ethics Committee (H-1-2011-157), and the Danish Data
Protection Agency (j.nr. 2007-58-0015), and is registered
at ClinicalTrials.gov (NCT01558765). Although guide-
lines recommend cardiac rehabilitation for patients after
heart valve surgery, evidence is lacking regarding its ef-
fectiveness. The extent of cardiac rehabilitation has been
very limited in Denmark, and the local ethics committee
agreed with the investigator group that we had a unique
opportunity to conduct a high-quality trial with a well-
described randomisation and blinded outcome evalu-
ation. All participants supply written informed consent.
The trial is conducted in accordance with the latest
edition of the Helsinki Declaration, and relevant regula-
tory requirements.
Objectives
We hypothesise that comprehensive cardiac rehabilita-
tion after heart valve surgery compared with treatment
as usual [7,25,26] improves physical capacity (at 4
months) measured by peak VO2 (oxygen uptake) by >3
mL/kg/min (primary outcome) [6,10,14,15,20,21,27], and
improves self-rated mental health (at 6 months) mea-
sured by Short Form 36 (SF-36), the mental health com-
ponent scale (secondary outcome) by 7 points [28,29].
The reason for choosing separately assessed outcome
times is due to the different durations of the two
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taken until 4 months post surgery and the psycho-
educational intervention until 6 months post surgery.
Further, the physical recovery is expected to be faster
than the mental recovery and therefore not comparable.
In exploratory analyses we will assess the effects of inte-
grated rehabilitation versus treatment as usual on a 6-
minute walk test, heart specific biomarkers (pro-brain
natriuretic peptide and copeptin [30]), and echocardio-
graphic measurements (diastolic function (E/A ratio), left
atrial size (mm), left atrial volume (mL)) [31,32]. Further-
more, we will assess the effects on time to return to work
after valve surgery, and long-term (24 months) employment
resignation [5,6,33], healthcare utilisation and mortality [8],
and cost effectiveness [33]. Standardised questionnaires:
Hospital Anxiety and Depression Scale [HADS] [34],
Quality of life Cardiac Version [QoL-CV], EQ-5D [35],
Heart Related Quality of Life [HeartQoL R] [36], Inter-
national Physical Activity Questionnaire [IPAQ] [37],
physical activity score and the Emotion and Health Scale
[38] will be applied to ascertain numerous exploratory
hypotheses concerning the possible effects of rehabilitation
on patient perceived physical and mental health.
Design
The CopenHeartVR trial is a multidisciplinary randomised
clinical superiority trial, allocating participants 1:1 to ex-
perimental intervention versus treatment as usual, with
blinded outcome assessment.
Alongside the trial we will conduct a number of com-
plementary studies; a survey-based study, to investigate
the post-discharge experiences and rehabilitation needs
of patients after heart valve surgery (approved by the
Danish Data Protection Agency, J.nr. 2011-41-6378);
a qualitative interview study of 10 patients aimed at
identifying patient experiences and needs after heart
valve surgery; a qualitative post-intervention study explor-
ing experiences of participating in a rehabilitation pro-
gramme; and register-based follow-up after 24 months
using appropriate registers described in methods section.
Thus, data from the survey based study and the ran-
domised clinical trial are supplemented by qualitative data,
and the two methods are integrated by applying a mixed
method embedded experimental design (Figure 1). The ra-
tionale for this approach is that quantitative findings pro-
vide a general understanding of the research problem
through statistical results, and subsequent qualitative find-
ings refine and explain the results by exploring partici-
pants’ views, thereby facilitating the implementation
process after trial completion [39,40].
This paper presents the detailed protocol for the
CopenHeartVR trial. The trial is described in accordance
with the current SPIRIT guidelines (Standard Protocol
Items: Recommendations for Interventional Trials [41]).Results will be reported following the CONSORT (CON
solidated Standards Of Reporting Trials) guidelines for
non-pharmacological interventions [42].
Participants
The trial is planned to include approximately 210 partic-
ipants of both sexes admitted to hospital for isolated
heart valve surgery.
Inclusion criteria are: patients admitted to hospital for
elective right-or left-sided heart valve surgery; age ≥18
years; speak and understand Danish; and informed
written consent.
Exclusion criteria are: known ischemic heart disease
prior to surgery, due to the documented effect of re-
habilitation in patients with ischemic disease [8,43];
recruited to other trials including physical exercise and
psycho-educational intervention, and participating in
other trials inhibiting participating in the present trial;
failure to understand and cooperate according to the
trial instructions; diseases in the musculoskeletal system
or other organs complicating physical activity and exercise
training; individuals performing hard physical exercise and
competitive sports several times weekly; pregnant and/or
breast-feeding women; and lack of informed consent.
Trial procedure and randomisation
Patient inclusion was initiated on 17 February 2012, and
recruitment is currently ongoing. Eligible patients are in-
vited by a nurse or medical doctor to a short consult-
ation on the second or third day after surgery, including
distribution of written participant information. Patients
needing further time to consider trial participation are
contacted by phone 1 week after discharge.
At enrolment, on average 3 to 5 days after surgery,
baseline data are collected (Table 1). A 6-minute walk
test is performed as close to discharge as possible, using
standard guidelines [44]. In case of postoperative com-
plications after enrolment, such as pericardial exudate
and atrial fibrillation, the patient’s case will be handled
individually, and the intervention will be postponed
according to recovery status. Participation in the trial
will never delay usual medical follow-up.
HADS, Hospital and Anxiety Depression Scale;
HeartQoL, Heart Disease Health-Related Quality of
Life; IPAQ, International Physical Activity Question-
naire; QoL-CV, Quality of Life Cardiac Version; SF-36,
Short Form 36.
After collection of baseline data, central randomisation
is conducted by telephoning the Copenhagen Trial Unit.
The randomisation is stratified for left ventricular ejec-
tion fraction (≥45% or <45%), and type of valve surgery
(sternotomy or percutaneous valve surgery, for example,
catheter-based surgery), and not for the valve involved.
Randomisation is conducted according to a computer-
Figure 1 The CopenHeartVR: trial design. The CopenHeartVR: Mixed methods embedded design comprises qualitative (QUAL) and quantitative
(QUAN) data, synthesized in a final analysis.
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concealed from the investigators to avoid selection bias.
Thus, neither investigators and patients nor relatives can
influence to which group the patients are allocated. Figure 2
shows patient flow throughout the trial.
Personal information about potential and enrolled pa-
tients will be collected electronically and shared in a
database accessible only within the project group for
those responsible for patient inclusion, in order to
protect confidentiality before, during and after the trial.
Control interventions
Both the intervention and the control group will receive
usual care. In accordance with current guidelines a
cardiologist sees all patients 4 to 6 weeks after heart
valve surgery [45,46]. At the follow-up visit a clinical
examination, biochemistry and echocardiography are
performed. All patients are given general information on
anticoagulation and endocarditis prophylaxis. During the
trial period the patients will be seen by a physician at
The Heart Centre, Rigshospitalet, for the follow-up visit,
after 1 and 4 months. All patients are instructed to initi-
ate their usual activities of daily living. Patients in the
control group have accepted not to receive local re-
habilitation at the hospital or community setting in their
written consent.
Experimental intervention
The experimental group undergoes the same interven-
tion as described above for the control group. In
addition, the experimental intervention consists of a
physical exercise training component and a psycho-
educational component.
The physical exercise component
The CopenHeart intervention has been developed and
partly tested in a clinical rehabilitation trial, the COPE-ICD trial [47], including patients with implantable
cardioverter defibrillator. We observed a significant im-
pact of the intervention on peak VO2, physical capacity
and self-assessed mental health. The intervention has
been modified for patients with heart valve surgery as
described below.
The CopenHeart physical exercise intervention meets
European [48] and Danish guidelines [49] for physical
exercise in patients with heart disease, and complies
with The National Danish Board of Health recommenda-
tions for physical exercise in daily living for heart pa-
tients [50].
The physical exercise starts 1 month post surgery after
the first cardiopulmonary exercise testing, and comprises
the following three elements:
Individual planning of the physical exercise. A spe-
cially trained physiotherapist conducts a patient consult-
ation of up to 30 min, integrating detailed information
concerning the specific heart valve disease, co-morbidity,
hospitalisation, activities of daily living, level of physical
activity prior to heart valve surgery, and results from
initial testing including cardiopulmonary exercise test 1
month post surgery, a 6-minute walk test, and a ‘sit and
stand’ test. The level of physical activity prior to heart
valve surgery is also monitored by a self-assessed ques-
tionnaire [51]. For all patients, a rehabilitation plan is
prepared as an individual training diary based on results
from the cardiopulmonary exercise test 1 month post
surgery, and the patients are instructed in the use of a
heart rate monitor (Polar Watch). The exercise diary
and the heart rate monitor recordings are essential in
monitoring and in assuring adherence to the interven-
tion. At the end of the intervention the diary and the
heart rate monitor are returned and compliance and
intensity level are coded independently.
Intensive physical exercise regimen. Physical exercise
is initiated at a physiotherapist supervised setting at the
Table 1 Data collection
Baseline 1 month 4 months 6 months 12 months 24 months Type of data
Background
Marital status x Categorical
Height, weight, body mass index x Continuous
Medical history
History of heart disease x Binary
Diabetes mellitus x Binary
Kidney diseasea x Binary
Chronic obstructive pulmonary disease (COPD)b x Binary
Hypertension x Binary
Dyslipidemiac x Binary
Medicine
Use of medication, self-reported x x x x Categorical
Heart valve specific questions
Type of heart valve disease x Categorical
Type of heart valve surgery x Categorical
NYHA classification x x x x x Categorical
Left ventricle ejection fraction (LVEF)d x x x Continuous
Euro SCORE IIe x Continuous
Postsurgical complications x x Binary
Postsurgical arrhythmiasf x x x Binary
Pacemaker post surgery x x x Binary
Clinical measurements
Biochemical screening x x x x Continuous
ECG x x Binary
Echocardiography x x Continuous
Physical testing
Six minute walk test x x x Continuous
Cardiopulmonary Exercise Testing x x x Continuous
Sit and stand test x x x Continuous
Questionnaires
Level of education x x Categorical
Employment status x x Categorical
Smoking x x Binary
SF-36g x x x x x x Continuous
HADS x x x x x x Continuous
QoL-CV x x x X Continuous
EQ-5Dg x X x x Continuous
HeartQoL x X x x Continuous
IPAQ x x x x Continuous
Physical activity score x x x X x x Categorical
Emotion and Health Scale x X Continuous
Rehabilitation receivedh X Categorical
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Table 1 Data collection (Continued)
Registry data assessment
Mortality, causes of death X Categorical
Hospitalisation X Continuous
Emergency room visits X Continuous
Outpatient clinic visits X Continuous
Contact with general practitioner X Continuous
Use of medication, register-based X Categorical
Employment status X Categorical
aKidney disease: patient history of kidney disease.
bCOPD: patient history of COPD, defined by FEV1 <70%.
cDyslipidemia: total plasma cholesterol >5 mmol/L.
dAt baseline: LVEF is pre surgery.
eEuropean System for Cardiac Operative Risk Evaluation includes patient-related factors, cardiac-related factors and operation-related factors to calculate the
predicted operative mortality for patients undergoing cardiac surgery.
fAtrial fibrillation, atrial flutter, malign arrhythmias.
gEQ-5D™ is a standardised instrument for use as a measure of health outcome from the EuroQoL group. hRehabilitation received: self-reported (Würgler MW et al.
Scand Jour Pub Health 2012, 40:126–132).
Screening for eligibility (n=?)
Exclusion (n=?)
Do not meet inclusion criteria 
Eligible patients (n=?)
Inclusion and exclusion criteria
Refused consent (n=?)
Informed written consent
Collection of baseline data 
Randomised allocation (1:1)
n= expected 210  
1 month post-surgery 
physical tests, questionnaires, echocardiography, biochemistry
12 months post surgery 
physical tests, questionnaires, biochemistry
24 month spost surgery 
registry follow-up, questionnaires
5 Nurse consultations every 4-6 week 
starting within the first month
Physical exercise training 3 times a week
for 12 weeks starting 1 month post- 
surgery
6 months post surgery
questionnaires, last nurse consultation
No intervention - Usual care
4 months post surgery 
physical tests, questionnaires, echocardiography, biochemistry
Control Group Intervention Group
Figure 2 The CopenHeartVR: trial diagram. The flow of patients through The CopenHeartVR. Participants in the intervention group follow an
integrated rehabilitation programme as described, and the control group follow standard care.
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ensure optimal healing and decrease the risk of un-
stable sternum. Using wireless electrodes integrated
into t-shirts (Corus-Fit, CardioCardio and Corus Exer-
cise Assistant, version 2.0.16, Finland) potential car-
diac arrhythmias, electrocardiographic abnormalities
such as ST segment changes, T-wave alterations, atrial
or ventricular arrhythmias, and training intensity level
are monitored. The training is initiated with one to
three mandatory exercise sessions in the primary in-
vestigating hospital, Rigshospitalet. Subsequently, the
patients can choose to continue the intensive physical
exercise regimen either in hospital at Rigshospitalet, at
a local CopenHeart-certified facility, supervised by
physiotherapists, or as supervised home-based train-
ing. Supervised home-based physical training has pre-
viously shown similar results to hospital-based training
[52]. This finding has been confirmed in a Danish set-
ting [53]. An exercise bicycle at home is required for
the patient to perform home-based exercise training.
The training programme continues for 12 weeks, com-
prising three sessions weekly of 60 min, 36 sessions
in total. The training protocol consists of cardiovas-
cular training and strength exercises due to the fact that
decreased exercise intolerance in heart valve patients
has been suggested to depend on decreased muscular
strength [54].
One session consists of 10 min warm-up bicycling, 20
min bicycling with increased intensity (cardiovascular train-
ing), 20 min strength exercises, and 10 min stretching and
cool-down period. The warm-up session is performed at
the intensity of 11–12 on the Borg scale [55]. The 20-min
cardiovascular training is performed as interval training.
Each session is divided into three sections. Each section
contains intensity 13–17 on the Borg scale and time limit
(2–15 min) varying between each section; the second sec-
tion with longest and highest intensity. A cool down period
of 5 min is included after the 20 min of cardiovascular
training.
The strength and strength-related exercises primarily
target lower body muscles, and comprise the following
four exercises: (1) Heel rise performed by repetitions of
maximal flexion from standing position; (2) Step-up by
using a step bench of 27 cm; (3) Leg press standardised,
starting with 90 degrees flexion, hyperextension not ac-
cepted; (4) 90 degrees pull-down performed in a cable
machine to target abdominal muscles. For step-ups and
heel-rises, weight load is calculated as a percentage of
body weight (5-20%) and increased throughout the 12
weeks. Load for leg press is estimated from repetition
maximum (RM) testing and increases from 60% of 1 RM
to 70% of 1 RM during the 12 weeks of training. Load
for 90 degree pull-downs is decided individually by the
physiotherapist assessed from the stabilisation of truncus.All exercises are initiated by 2x12 repetitions and increased
through the program according to standard guidelines for
strength training [56]. For home-based training two exer-
cises are modified (leg press and abdominal crunch).
Due to the fact of patients having had a sternotomy,
upper body strength training is not initiated before the
patient is pain free and at least 6 weeks post surgery
to avoid complications such as unstable sternum. To
achieve cardiovascular adjustment and reduce risk of
malignant cardiac arrhythmias, the training sessions are
initiated and terminated with a warm-up and cool-down
period, with a gradual decrease in training intensity.
Training is mainly performed in the upright position to
reduce left ventricle preload (diastolic volume).
Sustained moderate physical exercise daily. Patients
are guided individually to continue sustained moderate
physical exercise daily, and are instructed in maintaining
daily moderate physical exercise for at least 30 min dur-
ing the intervention period and afterwards throughout
their lives, for example, bicycling, walking, garden work,
jogging or ordinary exercise, and encouraged to use a
pedometer [57].
The psycho-educational component
The patients receive five consecutive nurse consultations
every 4 to 6 weeks during the first 6 months after
discharge, initiated within the first month. The consulta-
tions take place in a quiet setting at the outpatient clinic
or by telephone if the patient is unable to visit the
hospital, and are performed by cardiology nurses with
specific knowledge of patients with heart valve diseases,
after a special training module in the psycho-educational
intervention. Using a holistic patient view, the aim of the
consultation is to improve patients’ coping strategies,
disease management, provide information, and help re-
sume daily life after heart valve surgery. The information
given is based on national guidelines and standard treat-
ment of patients after heart valve surgery, and will cover
disease management including psychological challenges,
and the treatment such as technical and medical questions.
The intervention is inspired by R.R. Parse’s Human Be-
coming Practice Methodologies three dimensions [58]
interpreted as: (1) discuss and give meaning to the past,
present and future; (2) explore and discuss events and
possibilities; and (3) move along with envisioned possi-
bilities. According to the theory, three ways of changing
health are possible: (1) creative imaging; that is see, hear
and feel what a situation might be like if lived in a
different way; (2) affirming personal patterns and value
priorities; and (3) shedding light on paradoxes, that is,
looking at the incongruence in a situation and changing
the view held of something. The nurse is present in the
process through discussions, silent immersion and re-
flection, and is able to facilitate contact to or seek advice
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was chosen to apply a holistic patient approach centred
on the individual person’s themes for the consultations.
Furthermore, at The Heart Centre at Rigshospitalet, the
method is already extensively used in the outpatient
heart clinic, such as for patients with inherited heart dis-
eases and adults with congenital heart disease, and fully
documented in the COPE-ICD trial [59]. A consultation
guide is used to support the consultation (Table 2).
Reported issues for patients after heart valve surgery can
be: perceiving fragility, sleeping disturbances, body per-
ception, experiencing an information gap after hospital
discharge, and for some, symptoms of depression, anx-
iety and post-traumatic stress disorder, which will all be
covered when relevant [17,18].
Intervention deviations
Both the experimental interventions and the control
intervention will be supervised regularly to assure proto-
col compliance. Modification of the allocated interven-
tion due to complications of surgery, rehospitalisation or
emerging co-morbidities (for example, pneumonia, peri-
cardial exudation, musculoskeletal problems, atrial fibril-
lation) is always an individual decision, and the time ofTable 2 The psycho-educational intervention:
consultation guide
Questions Months after surgery
1 2 3 4 5-6
Discuss the events leading to heart
valve surgery. Experiences before,
during and after hospital admission.
x
Address present thoughts and questions. x x x x x
How have you been? What has happened
since you were here last time?
x x x x
How did you having heart valve surgery
affect your life? Are there things/activities
you avoid? Do you in any ways feel
impaired after having heart valve surgery?
x x x
Have you initiated exercise training?
How is training going?
x x x
Discuss social network/family. How do
they handle the situation? Has anything
changed in your social relationships?
x x x x
Has having heart valve surgery affected
your work situation? Has it had
financial consequences?
x
Have you had a changed view/perception
of your body and its functions?
x x
How is your health in relation to fatigue,
dyspnea, pain, appetite, gastrointestinal
function, sleep, sexual functioning, other?
x x x
Symptom handling and degree of dyspnea. x x x x x
Information/recommendations in relation
to discussed issues/problems according to
guidelines or if lacking to usual practice.
x x x x xthe measuring of primary outcome (described in section
below) at 4 months will be corrected in accordance with
changes in the intervention.
Outcomes and data collection
Primary outcome
Physical capacity is measured after 1 and 4 months by
peak VO2 using cardiopulmonary exercise testing (Ergo-
Spiro CS-200, Schiller, Switzerland), and is performed in
accordance with current guidelines [60]. An ergometer
bicycle is used, monitoring heart rate, blood pressure,
ECG and gas exchange during workload and in the re-
covery period. Optimal test duration is 8–10 min with a
pre- and post-test phase of 2–4 min. Gas, volume and
ambient calibration are performed before each session
to address changes in room temperature, humidity and
air O2 content. A ramp protocol is used with initial
workload of 25 or 50 watts, increasing by 12.5 watts/min
gradually until exhaustion. Exhaustion is evaluated by a
respiratory exchange ratio (RER) ≥1.10, reach of anaerobic
threshold [60], or the patient’s subjective exhaustion. The
peak V02 is determined after standard definitions [60] as
the highest V02 measured during the test.
The person who performs the test is either a medical
doctor or a nurse with cardiology patient experience. To
equally encourage patients independent of the person
present, a guide has been developed by the research
group, and regular supervision of each tester by a primary
investigator is maintained. For safety reasons, criteria for an
early test termination have been defined.
Secondary outcome
Self-assessed mental health is measured by the mental
health component scale of the SF-36 [61] at 1, 4 and
6 months.
Exploratory outcome measures
Register-based follow-up. Register data regarding mor-
tality, causes of death, hospitalisation/re-hospitalisation,
emergency room visits, outpatient visits, healthcare
costs, visits to the general practitioner, medication use,
employment status, and payment of welfare benefits
(sick leave payment and early retirement pension) will
be collected at 24 months to assess the long-term effect
of the intervention (Table 1). Danish registers for the
data mentioned above function well with only a small
percentage of lost data [62]. Consequently the method is
well suited as an outcome measure in small patient
populations. Data will be extracted from the Danish
National Patient Register [63], the Danish National
Health Service Register [64], the Danish National Pre-
scription Registry, the Danish National Causes of Death
Register [65], and records of transfer payments and
labour market affiliation [66,67].
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1, 4 and 12 months following randomisation (Table 1).
Questionnaires are also distributed at 6 and 24 months.
Six-minute walk test. The maximum walking distance
(in meters) within 6 min is measured using standardised
instructions [44], while subjective exhaustion with regard
to fatigue and dyspnoe before and after using the Borg
scale [55] is recorded.
Sit and stand test. The maximum number of times a
patient can sit and rise from a normal chair within 30 s.
Rate of perceived exertion is measured before and after
using the Borg scale.
Biochemical screening. C-reactive protein (CRP), urea,
glucose, haemoglobin, HbA1c, potassium, sodium, total
cholesterol, creatinine, HDL cholesterol, LDL cholesterol
and triglycerides. 1 EDTA plasma heparin tube will be
frozen (80°) for further analyses (pro-brain natriuretic
peptide and copeptin). The rationale for measuring chol-
esterol and triglyceride levels is to explore risk markers
for cardiovascular disease for this patient group.
Questionnaires. The patient’s perceived physical and
mental health will be analysed using relevant standardised
questionnaires as mentioned in the objectives section
(SF-36, HADS, QoL-CV, EQ-5D, HeartQoL, IPAQ and
Emotion and Health Scale).
Echocardiography. Two-dimensional Doppler echocar-
diography will be performed with standard techniques
(Philips iE33/ViCare, Denmark), corresponding to na-
tional and international guidelines for a full echocardiog-
raphy [68] including valve function, with focus on
diastolic function (E/A ratio), left atrial size (mm), and
left atrial volume (mL). Data will be analysed blinded to
randomisation group and time of echocardiography
using EchoPac/Excelera.
Economic evaluation
An economic evaluation will be conducted to assess the
cost-utility of cardiac rehabilitation. The economic evalu-
ation will compare the costs to quality-adjusted life years
(QALYs), and take a societal perspective as recommended
in Danish guidelines. QALYs and costs will be assessed at
the end of the intervention 6 months from randomisation
and later after 24 months from randomisation using
register-based follow-up.
QALYs will be estimated using the self-completed EQ-
5D instrument, which is a standardised instrument
assessing five dimensions of self-reported health status
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression) [69,70]. The estimated calculations
will be valued using Danish preference weights [71].
Information on costs will only include costs that are
expected to differ between the experimental intervention
and treatment as usual group [72]. Costs included costs
in the evaluation are health costs associated with therehabilitation programme, other healthcare costs (health
care utilisation besides rehabilitation), patient costs, and
costs of productivity losses. Information on costs will be
collected by a mixture of activity-based costing, surveys, pa-
tient diary, and registers.
Results from the analysis will be reported as an incremen-
tal cost-effectiveness analysis (ICER). Sensitivity-analyses
will be conducted to express uncertainty in the estimates
[73]. The reporting of ICER is presented using Bayesian
methods, including bootstrapping and presented as cost-
effectiveness acceptability curves [74].Statistical analysis
SPSS version 17.0 and SAS version 9.3 will be used for the
analyses. Data will be pseudo-anonymised and analysed
blinded by a trial-independent statistician using intention-
to-treat analyses, and a mixed model with repeated mea-
sures (MMRM) for continuous outcome measures [75].
Using MMRM ensures that missing data values (in the case
of the primary and secondary outcomes) will not create bias
as long as the values are missing at random. Two-sided
tests are performed. The level of significance is set at 5%.
Dealing with multiplicity, gate keeping will be used to ad-
just the observed P values for primary and secondary out-
comes [76]. Both unadjusted and adjusted P values will
be reported.
For the primary and secondary outcome measure, sen-
sitivity analysis will be conducted to assess the potential
impact of values missing not at random. For each inter-
vention group (A and B) some quantities (imputing
quantities) are computed to be used to impute missing
values in a group (A or B) as explained as follows. A
comparison between group A and group B where miss-
ing values in group A are imputed using imputing quan-
tities obtained from group A and missing values from
group B are imputed using imputing quantities obtained
from group B is referred to as a best-case analysis. If
missing values in group A are imputed using imputing
quantities obtained from group B and vice versa, the
comparison is called a worst-case analysis. The imputing
quantities for the primary outcome are the group mean
at T1 (X1-bar), the group mean at T4 (X4-bar), the
group mean at T6 (X6-bar), the mean difference be-
tween the value measured at T4 and that measured at
T1 (delta-1), and the mean difference between the value
measured at T6 and that measured at T4 (delta-2). The
quantities are used to impute missing values in a group
(either the same group or the other intervention group)
(Table 3). If the standard error (SE) of a parameter esti-
mate calculated using imputed data is smaller than that
of the corresponding parameter calculated using
complete case data, it is replaced by the latter SE when
the P value is calculated.
Table 3 The use of imputed values in CopenHeartVR
Observed pattern in group B at
1, 4 and 6 months
Imputed value in group B at
1 month
Imputed value in group B at
4 month
Imputed value in group B at
6 months
misa, mis, mis X1-barb X4-barc X6-bard
mis, mis, Y3e Y3 - (deltaf + delta2g)h Y3 - delta2
mis, Y2, mis Y2 – delta1 Y2 + delta2
Y1, mis, mis Y1 + delta1 Y1 + delta1 + delta2
Y1, Y2, mis Y2 + delta2
Y1, mis, Y3 (Y1 + delta1 + Y3 -delta2)/2
mis, Y2, Y3 Y2 - delta1
Table to explain the use of imputing quantities derived from observed values in a group (group A) to impute missing values in a group (group B).
aThe value at 4 months is missing in group B.
bMean of values observed in group A at 1 month.
cMean of values observed in group A at 4 months.
dMean of values observed in group A at 6 months.
eObserved value in group B at 6 months.
fThe mean of difference between values observed at 4 months and value observed at 1 month in group A.
gThe mean of difference between value observed at time 6 months and value observed at time 4 months in group A.
hIf an imputed value is 0 it is set equal to 0.
Mis, Missing value; X1, Value at month 1; X4, Value at month 4; X6, Value at month 6.
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two different models: non-negative count outcomes (for
example, number of contacts to hospital or number of
visits to general practitioners) will be analysed by a
Poisson model or a zero-inflated Poisson model if the
number of zeros are large, and time-to-event data (for
example, mortality and leaving the labour market) will
be analysed with survival methods (Kaplan-Meier esti-
mator and Cox regression model). Especially for socio-
economic outcomes, competing risks due to mortality
will be considered if a large proportion of patients die
during follow-up.
Exploratory outcome measures including data from
the 6-minute walk test, ‘sit and stand’ test, biochemical
screening and echocardiography will be analysed using
appropriate statistical methods.
Sample size and power calculation
We are performing a randomised trial with the continu-
ous variable VO2 peak from independent control and
intervention group participants as primary outcome with
one control per intervention group participant. Previous
studies report that VO2 peak is normally distributed in
the intervention and control groups with a standard de-
viation between 4.0 and 9.3 mL/kg/min [14,15,20,21],
though this might depend on the baseline peak VO2.
However, if the true difference between the intervention
and control group mean is 3 mL/kg/min [14,15,21], and
the standard deviation is 6 mL/kg/min, inclusion of 105
participants is needed in the experimental intervention
group, and 105 in the control group (a total of 210 par-
ticipants) to be able to reject the null hypothesis, stating
that the mean in the intervention and the control groups
are the same with a power of 95%, and a type I error
probability of 5%.The secondary outcome measure is the continuous
variable ‘mental health’. If the true difference between
the intervention and control group is 7 points, and the
standard deviation is 18 points [28,29], we will be able
to reject the null hypothesis that the population means
in the intervention and control group are equal with a
probability of 80%, and a type 1 error probability of 5%.
Discussion
The major strength of The CopenHeartVR is that it
includes consecutive patients with a reasonable number
of inclusion and exclusion criteria securing external
validity for the results. The trial employs central, strati-
fied randomisation, which secures against selection bias
[77-79]. The primary outcome is assessed blinded to
intervention, and so are all statistical analyses, which
should reduce detection and interpretation bias [77-79].
The long-term outcomes are based on registry data,
which are also likely not to include significantly biased
reporting of outcomes.
The secondary outcome of self-assessed mental health
is by nature subjective, and is likely to be biased [77-79].
The patients answer questionnaires independently of the
researchers. All questionnaires are distributed electron-
ically, thus data management is handled independently
from the researchers that interpret data. All data are stored
electronically in a coded database, and in an independent
spread sheet, only accessible for the CopenHeart Group.
The exploratory outcome measures highly impact the im-
portance of this study as very limited knowledge exists
concerning social and community outcomes for this patient
group.
The limitations of the trial and methods used are simi-
lar to those of other trials including physical exercise
and physical testing, which are time-of-day, and day-to-
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ard testing of all physical exercise tests in the trial,
standardised instructions for patients have been devel-
oped as described in the methods section. Including trial
patients with left- and right-side heart valve surgery will
result in an inhomogeneous trial population. Also, as
peak VO2 is dependent on exercise capacity, age or re-
covery capacities, which differ according to the valve in-
volved, consequently the expected results are going to
depend on the recruitment. Conversely, the trial popula-
tion will be representative of the broad heart valve pop-
ulation, and facilitate the external validity of The Copen
HeartVR rehabilitation programme in terms of daily clin-
ical practice.
The fact that patients have different options for their
intervention (home-based training, municipal setting or
continuous training at a heart centre in hospital setting),
and that the effect of the three different settings for
training are unknown, might influence the exercise
training, and thus the intervention, the primary and sec-
ondary outcome and exploratory analyses. However, pa-
tient compliance may be increased with different
options, and supervised home-based training for cardiac
patients has previously shown effective results compared
to centre-based training [52,81].
Finally, it has been shown that a substantial number of
patients allocated to the control group of a randomised
rehabilitation trial perform self-initiated physical exercise
training, possibly motivated by the trial information dur-
ing the recruitment process [82,83].
To conclude, The CopenHeartVR will be unique in
obtaining information on the organisation of rehabilita-
tion across sectors, and on how to optimise the transi-
tion phase after hospital discharge in order to initiate
and provide rehabilitation more rapidly, after heart valve
surgery. This is in accordance with current strategies for
future healthcare organisation as suggested by the World
Health Organization [84]. It is expected that results from
the trial will contribute to the development of heart
valve specific clinical rehabilitation guidelines, and to
identify requirements for resources within the field.
Safety aspects and Data Monitoring Safety Committee
(DMSC)
In supervised exercise training and testing of cardiac pa-
tient groups other than post heart valve surgery, the risk
of adverse effects is low (for example, ischemic heart dis-
ease, chronic heart failure), however, no current national
safety instructions exist. Patient safety is given the
highest priority, and exercise training after heart valve
surgery is considered safe based on results from exercise
testing and training with heart failure patients [85,86].
Any serious adverse events will be registered as part of
the data collection.The DMSC works independently from the funder and
has no competing interests, and consists of two clini-
cians and a statistician. The committee is responsible for
safeguarding the interests of trial participants, assessing
the safety and efficacy of the interventions during the
trial, and for monitoring the overall conduct of the cli-
nical trial. The steering committee and the DMSC com-
municate regularly, and at least every 9 months the
overall number of all serious adverse events is reported.
Trial status
The duration of inclusion is fixed at a maximum of 2
years to minimise the influence of changing treatment
trends on usual care intervention over time, and for trial
organisational reasons. Based on current activity levels
of valvular surgery at the Heart Centre, Rigshospitalet,
this can be achieved with an inclusion proportion of
35%. To achieve adequate participant enrolment, pa-
tients in doubt are contacted after hospital discharge by
phone, and another heart centre that is already in part-
nership with the trial will be invited to participate if the
enrolment rate declines. The inclusion rate is carefully
monitored every week.
Results of the trial and complementary studies will be
published in relevant international peer-reviewed journals.
Authorship will be determined according to the guidelines
of the International Committee of Medical Journal Editors.
Due to the comprehensiveness of the outcomes the results
will be presented in more than one scientific paper as rele-
vant. Economic and long-term follow-up will be reported
as data become accessible. Continuously updated informa-
tion about the trial is available at http://www.copenheart.
org/.
Conclusion
This randomised clinical trial, The CopenHeartVR, will be
the first trial to investigate the effect of an individually tai-
lored comprehensive cardiac rehabilitation programme
comprising physical exercise and a psycho-educational
intervention aimed at a broad group of patients after iso-
lated heart valve surgery in a municipal, hospital or home-
based setting. Due to its size, positive, negative or neutral
outcomes from The CopenHeartVR are likely to have an
impact on the organisation of and clinical guidelines for fu-
ture rehabilitation after heart valve surgery.
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